Wuhan Hvsen Biotechnology Co Ltd (300871) — Capital Reinvestment Ratio
Wuhan Hvsen Biotechnology Co Ltd (300871) has a Capital Reinvestment Ratio of 0.32x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥59.06 Million) in capital expenditures (CN¥18.73 Million). Check Wuhan Hvsen Biotechnology Co Ltd (300871) tangible net worth to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wuhan Hvsen Biotechnology Co Ltd Capital Reinvestment Ratio (2016–2025)
This chart tracks Wuhan Hvsen Biotechnology Co Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Wuhan Hvsen Biotechnology Co Ltd.
Annual Capital Reinvestment Ratio for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Year-by-year Capital Reinvestment Ratio for Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. See Wuhan Hvsen Biotechnology Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | CN¥238.45 Million | CN¥96.92 Million | ▼ -90.9% |
| 2024 | 4.47x | CN¥43.53 Million | CN¥194.43 Million | ▲ +125.2% |
| 2023 | 1.98x | CN¥92.92 Million | CN¥184.31 Million | ▼ -55.3% |
| 2022 | 4.44x | CN¥96.68 Million | CN¥428.87 Million | ▲ +15.1% |
| 2021 | 3.85x | CN¥155.72 Million | CN¥600.12 Million | ▼ -19.3% |
| 2020 | 4.77x | CN¥48.35 Million | CN¥230.84 Million | ▲ +308.3% |
| 2019 | 1.17x | CN¥105.24 Million | CN¥123.06 Million | ▼ -27.6% |
| 2018 | 1.61x | CN¥21.10 Million | CN¥34.05 Million | ▲ +130.6% |
| 2017 | 0.70x | CN¥80.56 Million | CN¥56.40 Million | ▲ +50.2% |
| 2016 | 0.47x | CN¥60.00 Million | CN¥27.97 Million | — |